Hormonal Correction of Menopausal Disorders in Patients with Burdened Oncological History of Serous Ovarian Cancer
O. V. Yakushevskaya,
S. V. Yureneva,
M. V. Averyanova,
O. I. Aleshikova,
N. A. Babaeva,
G. N. Khabas,
L. A. Ashrafyan https://doi.org/10.31550/1727-2378-2024-23-2-49-54
Abstract
Aim. To provide clinicians with a systematic review of the available information regarding the use of menopausal hormone therapy in women with induced menopause due to combined treatment of ovarian cancer.
Key points. Ovarian cancer is the eighth most common and seventh leading cause of cancer death. Menopausal hormone therapy is effective in correcting menopausal disorders, but its safety for patients who have had ovarian cancer is questioned.
Conclusion. In patients with a history of ovarian cancer, menopausal hormone therapy is currently thought to improve overall survival and has little to no effect on progression-free survival. However, due to the lack of information, the reliability of the results obtained requires further research in this area.
About the Authors
O. V. Yakushevskaya
National Medical Research Center for Obsterics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
4, Oparina Str., Moscow, 117997.
S. V. Yureneva
National Medical Research Center for Obsterics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
4, Oparina Str., Moscow, 117997.
M. V. Averyanova
National Medical Research Center for Obsterics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
4, Oparina Str., Moscow, 117997.
O. I. Aleshikova
National Medical Research Center for Obsterics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
4, Oparina Str., Moscow, 117997.
N. A. Babaeva
National Medical Research Center for Obsterics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
4, Oparina Str., Moscow, 117997.
G. N. Khabas
National Medical Research Center for Obsterics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
4, Oparina Str., Moscow, 117997.
L. A. Ashrafyan
National Medical Research Center for Obsterics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
4, Oparina Str., Moscow, 117997.
References
1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71(3): 209–249. DOI: 10.3322/caac.21660
2. Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.; 2021.[Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds.) Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow; 2021. (in Russian)]
3. Saeaib N., Peeyananjarassri K., Liabsuetrakul T. et al. Hormone replacement therapy a'er surgery for epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2020;(1):CD012559. DOI: 10.1002/14651858.CD012559.pub2
4. Vergote I., Denys H., De Greve J. Treatment algorithm in patients with ovarian cancer. Facts Views Vis. Obgyn. 2020;12(3):227–239.
5. Подзолкова Н.М., Коренная В.В. Онкопротективные эффекты гормональных контрацептивов. Гинекология. 2012;14(1):28. [Podzolkova N.M., Korennaya V.V. Oncoprotective effects of hormonal contraceptives. Gynecology. 2012;14(1):28. (in Russian)]
6. Hua H., Zhang H., Kong Q., Jiang Y. Mechanisms for estrogen receptor expression in human cancer. Exp. Hematol. Oncol. 2018;7(24):1–11. (in Russian). DOI: 10.1186/s40164-018-0116-7.
7. Юренева С.В., Аверьянова М.В., Ашрафян Л.А. и др. Патогенные варианты в генах BRCA 1,2: что важно знать практикующему гинекологу. Акушерство и гинекология. 2022;(11):52–59. [Yureneva S.V., Averyanova M.V., Ashrafyan L.A. et al. Pathogenic variants in genes BRCA 1,2: What is important for a practicing gynecologist to know. Obstetrics and gynecology. 2022;(11):52–59. (in Russian)]. DOI: 10.18565/aig.2022.11.52-59
8. Li S., Silvestri V., Leslie G. et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J. Clin. Oncol. 2022;40(14): 1529–1541. DOI: 10.1200/JCO.21.02112
9. Li H., Liu Y., Wang Y. et al. Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review). Oncol. Rep. 2021;46(4):223. DOI: 10.3892/or.2021.8174
10. Manson J.E., Chlebowski R.T., Stefanick M.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310:1353–1368. DOI: 10.1001/jama.2013.278040
11. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V., Gaitskell K. et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835–1842. DOI: 10.1016/S0140-6736(14)61687-1
12. Lowe K.A., Chia V.M., Taylor A., O'Malley C. An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol. 2013;130(1):107–114. DOI: 10.1016/j.ygyno.2013.03.026
13. Biglia N., Bounous V.E. Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas. 2015;82(3): 296–298. DOI: 10.1016/j.maturitas.2015.07.006
14. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. DOI: 10.1097/GME.0000000000002028
15. Del Carmen M.G., Rice L.W. Management of menopausal symptoms in women with gynecologic cancers. Gynecol. Oncol. 2017;146: 427–435. DOI: 10.1016/j.ygyno.2017.06.013
16. Eeles R.A., Morden J.P., Gore M. et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J. Clin. Oncol. 2015;33(35):4138–4144. DOI: 10.1200/JCO.2015.60.9719
17. Ursic-Vrscaj M., Bebar S., Zakelj M.P. Hormone replacement therapy a'er invasive ovarian serous cystadenocarcinoma treatment: the eHect on survival. Menopause. 2001;8(1):70–75. DOI: 10.1097/00042192-200101000-00012
18. Mascarenhas C., Lambe M., Bellocco R. et al. Use of hormone replacement therapy before and a'er ovarian cancer diagnosis and ovarian cancer survival. Int. J. Cancer. 2006;119(12):2907–2915. DOI: 10.1002/ijc.22218
19. Wen Y., Huang H., Wu M. et al. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric. 2013;16(6):673–81. DOI: 10.3109/13697137.2013.806472
20. Guidozzi F., Paponte A. Estrogen replacement therapy in ovarian cancer survivors. Int. J. Gynecol. Cancer. 1999;9(Suppl 1):5. DOI: 10.1002/(sici)1097-0142(19990915)86:6<1013::aid-cncr17>3.0.co;2-1
21. Li L., Pan Z., Gao K. et al. Impact of postoperative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncol. Lett. 2012;3(1):244–249. DOI: 10.3892/ol.2011.461
22. Pergialiotis V., Pitsouni E., Prodromidou A. et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis, Menopause. 2016;23:335–342. DOI: 10.1097/GME.0000000000000508
23. Baber R.J., Panay N., Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. DOI: 10.3109/13697137.2015.1129166
24. Rousset-Jablonski C., Selle F., Adda-Herzog E. et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. Eur. J. Cancer. 2019;116:35–44. DOI: 10.1016/j.ejca.2019.04.018
25. Rees M., Angioli R., Coleman R.L. et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020;134:56–61. DOI: 10.1016/j.maturitas.2020.01.005
26. Mendoza N., Ramírez I., de la Viuda E. et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65–85. DOI: 10.1016/j.maturitas.2022.08.008
27. Colombo N., Sessa C. ESMO–ESGO consensus conference reco- mmendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 2019;30:672–705. DOI: 10.1093/annonc/mdz062
28. Fleming G., Seidman J., Lengyel E. Epithelial ovarian cancer. In: Barakat R.R., Berchuck A., Markman M., Randall M.E. (eds.). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia; 2013:757–847.
Review
For citations:
Yakushevskaya O.V., Yureneva S.V., Averyanova M.V., Aleshikova O.I., Babaeva N.A., Khabas G.N., Ashrafyan L.A. Hormonal Correction of Menopausal Disorders in Patients with Burdened Oncological History of Serous Ovarian Cancer. Title. 2024;23(2):49-54. (In Russ.) https://doi.org/10.31550/1727-2378-2024-23-2-49-54
Views:
14
Email this article 